As AI per­me­ates clin­i­cal an­a­lyt­ics, Per­cep­tive Ad­vi­sors bets $40M in­to a sto­ried play­er in the field

When it comes to us­ing ar­ti­fi­cial in­tel­li­gence to speed up drug dis­cov­ery and de­vel­op­ment, the for­mer may be grab­bing the most at­ten­tion with the crop of AI up­starts vow­ing to find bet­ter can­di­dates faster and cheap­er, but the pos­si­bil­i­ty of ac­cel­er­at­ing ex­ist­ing clin­i­cal pro­grams is equal­ly en­tic­ing — if less vis­i­ble — to the bio­phar­ma in­dus­try.

That’s at least part of the ra­tio­nale be­hind Per­cep­tive Ad­vi­sors’ $40 mil­lion in­fu­sion in­to Saa­ma, a soft­ware com­pa­ny sell­ing a clin­i­cal da­ta an­a­lyt­ics plat­form pow­ered by AI.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER